Emfizatamab  (Synonyms: GNC-038)

Emfizatamab (GNC-038) is a monoclonal antibody against CD19/CD3E/TNFRSF9/PD-L1. Emfizatamab exhibits antitumor activity, being capable of activating CD3 and 4-1BB signals on T cells, as well as targeting the high expression of CD19 or PD-L1 on tumor cells. Emfizatamab functions as a CD19-specific T cell engager by mediating direct antitumor activity. Emfizatamab can also overcome the inhibition of T cells by PD-L1. Emfizatamab can be used in the research of tumors such as R/R non-Hodgkin lymphoma or acute lymphoblastic leukemia^[1][2].

(scFv-kappa-heavy)-G1_L-kappa-(scFv-heavy-kappa)-(scFv-heavy-kappa)

Human IgG1 kappa, Isotype Control

Human

CD19 & CD3E & TNFRSF9 & PD-L1

Emfizatamab can effectively mediate the killing of CD19+ tumor cells by T cells, and the T cell degranulation and IFN-γ production induced by it are similar to those of Blinatumomab (HY-P9963)^[2].
Emfizatamab (48 h) produces more IFN-γ, IL-2 and TNF-α in peripheral blood mononuclear cells (PBMC) compared to Blinatumomab, but there is no significant difference in IL-6 production^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

930  [NCBI] & 916  [NCBI] & 3604  [NCBI]

P15391 & P07766 & Q07011 & Q9NZQ7

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

303.229 kDa

2559704-23-1

Liquid

Colorless to off-white

[Emfizatamab]

Shipping with dry ice.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  (scFv-kappa-heavy)-G1_L-kappa-(scFv-heavy-kappa)-(scFv-heavy-kappa)

• 
  Immobilized CD3 epsilon Protein, Human (HEK293, His, HY-P70506) can bind Emfizatamab. The EC₅₀ for this effect is 27.4 ng/mL.
• 
  Immobilized CD19 Protein, Human (HEK293, His, HY-P74330) can bind Emfizatamab. The EC₅₀ for this effect is 57.29 ng/mL.
• 
  Immobilized 4-1BB/TNFRSF9 Protein, Human, HY-P7125) can bind Emfizatamab. The EC₅₀ for this effect is 1.358 ng/mL.
• 
  Immobilized PD-L1 Protein, Human (HEK293, HY-P73361) can bind Emfizatamab. The EC₅₀ for this effect is 64.84 ng/mL.

• [1]. Wang J, et al. GNC-038, a tetra-specific antibody, in patients with R/R non-Hodgkin lymphoma or acute lymphoblastic leukemia: A phase 1 study design and rationale. 2023.

  [2]. Khalili JS, Xiao S, Zhu Y. Tetra-specific antibody GNC-038: guidance and navigation gontrol (GNC) molecule development for treatment of CD19+ malignancies. Cancer Research. 2023 Apr 4;83(7_Supplement):5681-.